Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease .
In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 . In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 .
Memantine is used to manage moderate to severe Alzheimer's dementia .
A more recent systemic review and meta-analysis indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia .
Institute of Psychiatry, London, United Kingdom
CA019, Edmonton, Alberta, Canada
CA005, Beauport, Quebec, Canada
CA009, Toronto, Ontario, Canada
CA022, St. John, New Brunswick, Canada
CA043, Kelowna, British Columbia, Canada
CA009, Toronto, Ontario, Canada
DE001, Munich, Germany
Ambulatory Research Center, Minneapolis, Minnesota, United States
University of Minnesota, Minneapolis, Minnesota, United States
University Clinic Gustav Carus, Dresden, Saxony, Germany
Department of Psychogeriatrics,Shanghai Mental Health Center, Shanghai, Shanghai, China
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Peking University Institute of Mental Health, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.